The Comparative Oncology Trials Consortium at the National Cancer Institute have been performing canine glioma pre-clinical trials to evaluate therapeutic strategies that could benefit both dogs and humans. However, the similarity between human and canine glioma at the molecular and genomic level is unknown. Researchers recently addressed this knowledge gap by reporting on the genomic landscape of canine glioma, to demonstrate that this is similar to the genomic landscape of human glioma, and pediatric high-grade glioma in particular. This project will use high-throughput functional screens of canine and human glioma model systems, to identify and prioritize genes as potential drug targets for glioma therapy. This research will provide a basis for the development of new therapies and repurposing of existing drugs for children and dogs with brain cancer. The Children’s Brain Tumor Network supports this project through the provision of pediatric high-grade glioma data resources and cell lines.
What are the goals of this project?
Researchers are looking to identify targetable genes in pediatric and canine glioma that can be exploited for new therapies.
What is the impact of this project?
This research will provide data necessary to move forward with the development of new glioma therapies and the repurposing of existing drugs for use in canines and pediatric brain cancer patients.
Why is the CBTN request important to this project?
This comparative work is made possible through the provision of samples and data by the Children’s Brain Tumor Network.
The Children's Brain Tumor Network will contribute to this project by providing cell lines.
The Jackson Laboratory
More than 2,300 employees are working toward one goal — to discover precise genomic solutions for disease and empower the global biomedical community in our shared quest to improve human health.The Jackson Laboratory (JAX) is a world leader in mammalian genetics and human genomics research. Founded
High-grade Gliomas (HGG) or astrocytomas in children nearly always result in a dismal prognosis. Although novel therapeutic approaches are currently in development, preclinical testing has been limited, due to a lack of pediatric-specific HGG preclinical models. These models are needed to help test